Foster City, CA Breaking News Headlines Today

News about Foster City

Stay current with all the latest and breaking news about Foster City, compare headlines and perspectives between news sources on stories happening today. In total, 39 stories have been published about Foster City which Ground News has aggregated in the past 3 months.

Local News Publishers

Untracked bias

Suggest a source

Looking for a source we don't already have? Suggest one here.

Heitman to List 400,000 SQFT Parkside Towers Office Campus in Foster City

Investment firm seeks exit from Class A Peninsula property after decade-long hold amid stabilizing but challenged market Heitman will be putting Parkside Towers, a 400,000-square-foot Class A office campus in Foster City, on the market for sale, according to industry sources who spoke with The Registry. Eastdil Secured is marketing the two-tower property at 1001-1051 […] The post Heitman to List 400,000 SQFT Parkside Towers Office Campus in Fost…Foster City · Foster City Read Article

Gilead Sciences (NASDAQ:GILD) Sets New 52-Week High Following Analyst Upgrade

100% Center coverage: 1 sources

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday after Leerink Partners raised their price target on the stock from $114.00 to $146.00. Leerink Partners currently has an outperform rating on the stock. Gilead Sciences traded as high as $142.20 and last traded at $141.53, with a volume of 8928 shares trading hands. The stock had previously closed at $141.95. A number of other bro…Gilead Sciences · Foster City Read Article

Leerink Partners Increases Gilead Sciences (NASDAQ:GILD) Price Target to $146.00

100% Center coverage: 1 sources

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price increased by analysts at Leerink Partners from $114.00 to $146.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ price objective would indicate a potential upside of 2.85% from the company’s previous close. Other equities researc…Foster City · Foster City Read Article

Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

100% Center coverage: 1 sources

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. The trade was a 1.76% decrease in their positi…Gilead Sciences · Foster City Read Article

MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease

FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ — MicuRx Pharmaceuticals, Inc. (“MicuRx”), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical […]Foster City · Foster City Read Article

Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

100% Center coverage: 1 sources

Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective raised by Truist Financial from $140.00 to $145.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on GILD. Mizuho lifted their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a…Gilead Sciences · Foster City Read Article

GSK's (GSK) "Buy" Rating Reaffirmed at Citigroup

100% Center coverage: 2 sources

Citigroup reiterated a "buy" rating and issued a GBX 1,900 price objective on shares of GSK in a research note on Tuesday.Gilead Sciences · Foster City See the Story

Worried About AI Stock Valuations? This REIT Trades at a Fraction of the Price.

100% Left coverage: 1 sources

Key PointsThere are other ways to invest in the artificial intelligence (AI) revolution besides chipmakers and software companies. Equinix provides the infrastructure that allows the hardware behind AI to operate reliably. The stock trades for a very reasonable valuation relative to its opportunity.10 stocks we like better than Equinix › There's no denying it -- artificial intelligence (AI) is the most transformative technological revolution in …Artificial Intelligence · Foster City Read Article

Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD

100% Center coverage: 1 sources

Mn Services Vermogensbeheer B.V. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 474,555 shares of the biopharmaceutical coFoster City · Foster City Read Article

Gilead Sciences (NASDAQ:GILD) Director Sells $617,500.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. […]Foster City · Foster City Read Article

News about Foster City

News about Foster City

Local News Publishers Too Big Arrow Icon

Heitman to List 400,000 SQFT Parkside Towers Office Campus in Foster City

Gilead Sciences (NASDAQ:GILD) Sets New 52-Week High Following Analyst Upgrade

Leerink Partners Increases Gilead Sciences (NASDAQ:GILD) Price Target to $146.00

Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease

Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

GSK's (GSK) "Buy" Rating Reaffirmed at Citigroup

Worried About AI Stock Valuations? This REIT Trades at a Fraction of the Price.

Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Director Sells $617,500.00 in Stock

Local News Publishers Too Big Arrow Icon

Breaking News Topics Related to Foster City

Heitman to List 400,000 SQFT Parkside Towers Office Campus in Foster City

Gilead Sciences (NASDAQ:GILD) Sets New 52-Week High Following Analyst Upgrade

Leerink Partners Increases Gilead Sciences (NASDAQ:GILD) Price Target to $146.00

Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease

Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

GSK's (GSK) "Buy" Rating Reaffirmed at Citigroup

Worried About AI Stock Valuations? This REIT Trades at a Fraction of the Price.

Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Director Sells $617,500.00 in Stock

Local News Publishers

Local News Publishers